晚期肾癌的分子靶向治疗

doi:10.3760/cma.j.issn.1673-422X.2019.12.001

摘要/Abstract

摘要： 索拉非尼是首个用于晚期肾癌患者一线治疗的分子靶向药物，并获得了满意的疗效。之后陆续出现了多种分子靶向药物，从此对晚期肾癌患者的治疗进入了分子靶向新时代。分子靶向治疗提高了患者临床疗效、治疗反应率，延长了患者无进展生存期和总生存期。目前的靶向药物包括血管内皮生长因子抑制剂、哺乳动物雷帕霉素靶蛋白抑制剂、免疫检查点抑制剂等。了解不同靶向药物的作用机制和临床疗效，同时从基因突变和耐药性角度分析目前靶向药物面临的挑战，有助于晚期肾癌患者的个性化治疗。

关键词: , 肾肿瘤, 泌尿系肿瘤, 分子靶向治疗, 抗肿瘤药物, 个性化医学

Abstract: Sorafenib is the first molecularly targeted drug for first-line treatment of patients with advanced kidney cancer and has achieved satisfactory results. Since then, a variety of molecularly targeted drugs have emerged, and the treatment of patients with advanced kidney cancer has entered a new era of molecular targeting. Molecular targeted therapy improves the clinical efficacy and response rate of patients, and prolongs the progression-free survival and overall survival of patients. Current targeted drugs include vascular endothelial growth factor inhibitors, mammalian target of rapamycin, immunological checkpoint inhibitors, etc. Understanding the mechanism of action and clinical efficacy of different targeted drugs, and analyzing the challenges of current targeted drugs from the perspective of gene mutation and drug resistance are helpful to the personalized treatment of patients with advanced renal cancer.

Key words: , Kidney neoplasms, Urologic neoplasms, Molecular targeted therapy, Antineoplastic agents, Precision medicine

熊波波, 张劲松, 李宁, 王海峰, 左毅刚, 王剑松. 晚期肾癌的分子靶向治疗[J]. 国际肿瘤学杂志, 2019, 46(12): 705-710.

Xiong Bobo, Zhang Jinsong, Li Ning, Wang Haifeng, Zuo Yigang, Wang Jiansong. Molecular targeted therapy for advanced kidney cancer[J]. Journal of International Oncology, 2019, 46(12): 705-710.

参考文献［42］

［1］	Mokdad AH, Dwyer-Lindgren L, Fitzmaurice C, et al. Trends and patterns of disparities in cancer mortality among US counties, 1980-2014［J］. JAMA, 2017, 317(4): 388-406. DOI: 10.1001/jama.2016.20324.
［2］	Klaassen Z, Sayyid RK, Wallis C. Lessons learned from the global epidemiology of kidney cancer: a refresher in epidemiology 101［J］. Eur Urol, 2019, 75(1): 85-87. DOI: 10.1016/j.eururo.2018.09.035.
［3］	Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma［J］. Eur Urol, 2019, 75(1): 74-84. DOI: 10.1016/j.eururo.2018.08.036.
［4］	Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions［J］. CA Cancer J Clin, 2017, 67(6): 507-524. DOI: 10.3322/caac.21411.
［5］	Brown C. Targeted therapy: an elusive cancer target［J］. Nature, 2016, 537(7620): S106-S108. DOI: 10.1038/537S106a.
［6］	Brugarolas J. Molecular genetics of clear-cell renal cell carcinoma［J］. J Clin Oncol, 2014, 32(18): 1968-1976. DOI: 10.1200/JCO.2012.45.2003.
［7］	Liu T, Li J, Wen X, et al. Sorafenib improves the postoperative effect of early stage renal cell carcinoma［J］. Oncol Lett, 2016, 12(6): 4367-4370. DOI: 10.3892/ol.2016.5243.
［8］	Hu D, Hu Y, Li J, et al. Symptomatic treatment of brain metastases in renal cell carcinoma with sorafenib［J］. J Cancer Res Ther, 2018, 14(Supplement): S1223-S1226. DOI: 10.4103/0973-1482.189402.
［9］	Joshi A, Ramaswamy A, Noronha V, et al. Efficacy and safety of sorafenib in advanced renal cell cancer and validation of heng criteria［J］. Indian J Cancer, 2016, 53(3): 423-428. DOI: 10.4103/0019-509X.200662.
［10］	Baker H. Sunitinib as adjuvant therapy for renal cell carcinoma［J］. Lancet Oncol, 2016, 17(11): e485. DOI: 10.1016/S1470-2045(16)30511-3.
［11］	Noize P, Grelaud A, Bay JO, et al. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the santorin cohort study［J］. Pharmacoepidemiol Drug Saf, 2017, 26(12): 1561-1569. DOI: 10.1002/pds.4228.
［12］	Keizman D, Sarid D, Lee JL, et al. Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib［J］. Oncologist, 2016, 21(10): 1212-1217. DOI: 10.1634/theoncologist.2015-0428.
［13］	蔡文, 袁易初, 李明阳, 等. 索拉非尼和舒尼替尼一线治疗转移性肾癌的疗效比较及预后分析［J］. 中华肿瘤杂志, 2018, 40(5): 384389. DOI: 10.3760/cma.j.issn.02533766.2018.05.012.
［14］	Melichar B, Procházková-Sˇtudentová H, Vitásková D. Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the avoren trial［J］. Expert Rev Anticancer Ther, 2012, 12(10): 1253-1261. DOI: 10.1586/era.12.103.
［15］	Schultze-Seemann W, Schulz H, Tschechne B, et al. Bevacizumab plus IFN-alpha-2a in first-line treatment of patients with advanced or metastatic renal cell carcinoma: a prospective german non-interventional study［J］. Anticancer Res, 2019, 39(2): 875-882. DOI: 10.21873/anticanres.13188.
［16］	Miyamoto S, Kakutani S, Sato Y, et al. Drug review: pazopanib［J］. Jpn J Clin Oncol, 2018, 48(6): 503-513. DOI: 10.1093/jjco/hyy053.
［17］	Stein J, Milhem M, Vaena D. Clinical outcomes and toxicities of pazopanib administered orally in crushed form: case reports and review of the literature［J］. J Oncol Pharm Pract, 2019, In press. DOI: 10.1177/1078155219841108.
［18］	Schmidinger M, Bamias A, Procopio G, et al. Prospective observational study of pazopanib in patients with advanced renal cell carcinoma (principal study)［J］. Oncologist, 2019, 24(4): 491-497. DOI: 10.1634/theoncologist.2018-0787.
［19］	Miyake H, Harada K, Ozono S, et al. Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma［J］. Med Oncol, 2016, 33(8): 95. DOI: 10.1007/s12032-016-0813-1.
［20］	Hutson TE, Al-Shukri S, Stus VP, et al. Axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a randomized phase Ⅲ trial［J］. Clin Genitourin Cancer, 2017, 15(1): 72-76. DOI: 10.1016/j.clgc.2016.05.008.
［21］	Al-Salama ZT, Keating GM. Cabozantinib: a review in advanced renal cell carcinoma［J］. Drugs, 2016, 76(18): 1771-1778. DOI: 10.1007/s40265-016-0661-5.
［22］	Amzal B, Fu S, Meng J, et al. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: a network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma［J］. PLoS One, 2017, 12(9): e0184423. DOI: 10.1371/journal.pone.0184423.
［23］	Stone L. Lenvatinib shows promise［J］. Nat Rev Urol, 2015, 12(12): 654. DOI: 10.1038/nrurol.2015.262.
［24］	Roviello G, Corona SP, Bozza G, et al. Lenvatinib for the treatment of renal cell carcinoma［J］. Expert Opin Investig Drugs, 2018, 27(5): 507-512. DOI: 10.1080/13543784.2018.1472235.
［25］	De Lisi D, De Giorgi U, Lolli C, et al. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy［J］. Expert Opin Drug Metab Toxicol, 2018, 14(4): 461-467. DOI: 10.1080/17425255.2018.1455826.
［26］	Zanardi E, Verzoni E, Grassi P, et al. Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma［J］. Ther Adv Urol, 2015, 7(3): 152-161. DOI: 10.1177/1756287215574457.
［27］	Damayanti NP, Budka JA, Khella H, et al. Therapeutic targeting of TFE3/IRS-1/PI3K/mTOR axis in translocation renal cell carcinoma［J］. Clin Cancer Res, 2018, 24(23): 5977-5989. DOI: 10.1158/1078-0432.CCR-18-0269.
［28］	Satoh T, Koie T, Horiguchi H, et al. Longer recurrence-free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus［J］. Clin Case Rep, 2017, 5(12): 1950-1953. DOI: 10.1002/ccr3.1181.
［29］	Harshman LC, Kroeger N, Rha SY, et al. First-line mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the international metastatic renal cell carcinoma database consortium［J］. Clin Genitourin Cancer, 2014, 12(5): 335-340. DOI: 10.1016/j.clgc.2014.03.003.
［30］	Schrader AJ, Seseke S, Keil C, et al. Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer［J］. Eur Urol, 2014, 66(2): 275-281. DOI: 10.1016/j.eururo.2013.08.055.
［31］	Maráz A, Csejtei A, Kocsis J, et al. Assessment of the role of everolimus therapy in patients with renal cell carcinoma based on daily routine and recent research results［J］. Pathol Oncol Res, 2019, 25(1): 149-156. DOI: 10.1007/s12253-017-0317-0.
［32］	Guida A, Albiges L, Derosa L, et al. Everolimus versus axitinib as second-line therapy in metastatic renal cell carcinoma: experience from institut gustave roussy［J］. Clin Genitourin Cancer, 2017, 15(6): e1081-e1088. DOI: 10.1016/j.clgc.2017.07.015.
［33］	Atkins MB, Clark JI, Quinn DI. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions［J］. Ann Oncol, 2017, 28(7): 1484-1494. DOI: 10.1093/annonc/mdx151.
［34］	Choueiri TK, Fishman MN, Escudier B, et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma［J］. Clin Cancer Res, 2016, 22(22): 5461-5471. DOI: 10.1158/1078-0432.CCR-15-2839.
［35］	Alsharedi M, Katz H. Check point inhibitors a new era in renal cell carcinoma treatment［J］. Med Oncol, 2018, 35(6): 85. DOI: 10.1007/s12032-018-1147-y.
［36］	Mendiratta P, Rini BI, Ornstein MC. Emerging immunotherapy in advanced renal cell carcinoma［J］. Urol Oncol, 2017, 35(12): 687-693. DOI: 10.1016/j.urolonc.2017.08.011.
［37］	Gao X, McDermott DF. Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma［J］. Expert Opin Biol Ther, 2018, 18(9): 947-957. DOI: 10.1080/14712598.2018.1513485.
［38］	Mitchell TJ, Rossi SH, Klatte T, et al. Genomics and clinical correlates of renal cell carcinoma［J］. World J Urol, 2018, 36(12): 1899-1911. DOI: 10.1007/s00345-018-2429-x.
［39］	Bihr S, Ohashi R, Moore AL, et al. Expression and mutation patterns of PBRM1, BAP1 and SETD2 mirror specific evolutionary subtypes in clear cell renal cell carcinoma［J］. Neoplasia, 2019, 21(2): 247-256. DOI: 10.1016/j.neo.2018.12.006.
［40］	Makhov P, Joshi S, Ghatalia P, et al. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies［J］. Mol Cancer Ther, 2018, 17(7): 1355-1364. DOI: 10.1158/1535-7163.MCT-17-1299.
［41］	Wan YP, Xi M, He HC, et al. Expression and clinical significance of SOX9 in renal cell carcinoma, bladder cancer and penile cancer［J］. Oncol Res Treat, 2017, 40(1-2): 15-20. DOI: 10.1159 / 000455145.
［42］	Ishibashi K, Koguchi T, Matsuoka K, et al. Interleukin-6 induces drug resistance in renal cell carcinoma［J］. Fukushima J Med Sci, 2018, 64(3): 103-110. DOI: 10.5387/fms.2018-15.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[5]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[6]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[7]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[8]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[9]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[10]	刘利, 朱思齐, 孙梦颖, 何敬东. PARP抑制剂在小细胞肺癌靶向治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(6): 368-372.
[11]	刘博翰, 黄俊星. 溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[12]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[13]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[14]	刘绍平, 罗汉传, 林书瀚, 罗家辉. 中晚期肝细胞癌介入及系统治疗的现状与研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 758-762.
[15]	江山, 徐细明. 肝细胞癌的靶向及免疫治疗新进展[J]. 国际肿瘤学杂志, 2023, 50(11): 688-695.